Eisai Co., Ltd.
Clinical trials sponsored by Eisai Co., Ltd., explained in plain language.
A Japanese pharmaceutical company known for neurology and oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug E7386 tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …
Phase: PHASE1, PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug safety check for Hard-to-Treat lymphoma patients
Disease control OngoingThis study monitors the safety of the drug tazemetostat in 145 people with a type of lymphoma (follicular lymphoma) that has come back or not responded to treatment and has a specific gene change (EZH2 mutation). Researchers are tracking side effects and serious reactions during …
Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC